Trial results

Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

NCT07547878 on ClinicalTrials.gov · last registry update 2026-10-13

64 participants. Due to report 31 March 2029, alongside 11 other tracked readouts that quarter. Primary outcome, as filed: On-study retention rate at 6 months. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for chronic kidney disease and type 2 diabetes, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.

Status

ENROLLING_BY_INVITATION

Phase

P4

Drug

semaglutide

Ozempic, Rybelsus, Wegovy

Sponsor

Baylor Research Institute

Sponsor type

Other

Enrollment

64

Started

2026-04-08

Primary completion

2029-03-31 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

On-study retention rate at 6 months

Conditions studied

Chronic Kidney Disease · Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.